Vantage Nutrition, an ACG group company, has taken full shareholding ownership of ComboCap Inc (USA) and BioCap (South Africa).

In a statement, the company said that the acquisition marks a significant milestone for Vantage Nutrition and ACG, as it further expands its technology and customer solutions footprint in North America and around the world.

With this expansion of manufacturing capabilities and patented technology, along with providing integrated solutions and cutting-edge technology, Vantage Nutrition aims to provide the most comprehensive and advanced multiphase solutions to customers globally.

Karan Singh, managing director at ACG, said: “As one of world’s largest producers of empty hard-shell capsules, at ACG we have often thought, what next? Strengthening our portfolio of most comprehensive vegetarian and gelatin capsules, in every imaginable size, I am thrilled to announce the acquisition of ComboCap Inc and BioCap.”

Singh added: “We now will hold the patented design and specialized equipment used in producing the world’s first 2-in-1 capsule product with a movable membrane, becoming the sole proprietor of this technology globally.

“With our partners, we will usher a new era in new combinations of dietary supplements, and even non-prescription or over-the counter (OTC) remedies as well as prescription (Rx) medicines to be delivered in a single dose,” said Tobie Louw, a founder and CEO of ComboCap Inc.”This technological breakthrough is a solution to current formulation challenges with many combination therapies, including incompatible ingredients or molecules. Capsules are arguably the safest and most reliable way to deliver medicine and we at ACG strive to make it better.

“Vantage Nutrition is the perfect partner for our business, and we are very excited to be part of the ACG family. We share a passion for innovation and the commitment to bring nutraceutical and pharmaceutical customers the best possible solutions and services.”

Louw added: “By joining forces and leveraging our collective capabilities we’ll no doubt bring Sidebyside to nutraceutical and pharmaceutical markets the world over.”